Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PCVX Vaxcyte Inc
- Stocks
- Healthcare
- NASDAQ: PCVX
Price (delayed)
$31.16
Market cap
$4.02B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.99
Enterprise value
$3.76B
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious
Highlights
PCVX's quick ratio is up by 38% since the previous quarter
Vaxcyte's equity has surged by 61% YoY but it has decreased by 3.2% QoQ
The EPS has increased by 7% YoY but it has decreased by 5% from the previous quarter
The debt is up by 22% since the previous quarter
The net income has contracted by 17% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of PCVX
Market
Valuations
Earnings
Shares outstanding
129M
Market cap
$4.02B
Enterprise value
$3.76B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$635.87M
Net income
-$509.63M
EBIT
-$509.63M
EBITDA
-$492M
Free cash flow
-$593.62M
Per share
Balance sheet
Liquidity
EPS
-$3.99
EPS diluted
-$3.99
Free cash flow per share
-$4.37
Book value per share
$24.85
Revenue per share
$0
TBVPS
$24.9
Total assets
$3.38B
Total liabilities
$178.08M
Debt
$87.21M
Equity
$3.2B
Working capital
$1.62B
Debt to equity
0.03
Current ratio
17.7
Quick ratio
17.24
Net debt/EBITDA
0.53
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-16.3%
Return on equity
-17.1%
Return on invested capital
-20.4%
Return on capital employed
-15.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCVX stock price
How has the Vaxcyte stock price performed over time
Intraday
-0.92%
1 week
-11.95%
1 month
1.17%
1 year
-52.48%
YTD
-61.94%
QTD
-17.48%
Financial performance
How have Vaxcyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$635.87M
Net income
-$509.63M
Gross margin
N/A
Net margin
N/A
Vaxcyte's operating income has decreased by 24% YoY and by 12% QoQ
The net income has contracted by 17% YoY and by 10% from the previous quarter
Price vs fundamentals
How does PCVX's price correlate with its fundamentals
Growth
What is Vaxcyte's growth rate over time
Valuation
What is Vaxcyte stock price valuation
P/E
N/A
P/B
1.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 7% YoY but it has decreased by 5% from the previous quarter
The P/B is 67% lower than the 5-year quarterly average of 3.8 and 60% lower than the last 4 quarters average of 3.1
Vaxcyte's equity has surged by 61% YoY but it has decreased by 3.2% QoQ
Efficiency
How efficient is Vaxcyte business performance
PCVX's ROIC has soared by 52% year-on-year and by 8% since the previous quarter
Vaxcyte's return on equity has increased by 41% YoY
PCVX's ROA is up by 39% YoY
Dividends
What is PCVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCVX.
Financial health
How did Vaxcyte financials performed over time
The total liabilities has surged by 66% year-on-year but it has declined by 13% since the previous quarter
The company's total assets has surged by 62% YoY but it fell by 3.8% QoQ
The debt is 97% smaller than the equity
The company's debt to equity has surged by 200% YoY and by 50% QoQ
Vaxcyte's equity has surged by 61% YoY but it has decreased by 3.2% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.